Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;18(6):445-455.
doi: 10.2174/1389201018666170601091205.

Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application

Affiliations
Review

Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application

Seung-Hyun Kim et al. Curr Pharm Biotechnol. 2017.

Abstract

Background: Biomarkers are indispensable tools for screening, diagnosis, and prognosis in cardiovascular diseases and their clinical application increases steadily. As cardiovascular diseases include various pathophysiological processes, no single biomarker, even natriuretic peptides, can be regarded as ideal fulfilling all necessary criteria for a comprehensive diagnostic or prognostic assessment revealing optimal clinical application. Hence, multi-marker approaches using different biomarkers reflecting different pathophysiologies were highlighted recently. Advances in biomedical technologies expanded the spectrum of novel blood-derived biomarkers, such as micro-RNA (miRNA) or "omics"- data potentially providing a more advanced knowledge about pathogenesis of cardiovascular disease.

Conclusion: This review describes the advantages and limitations of blood circulating biomarkers with regard to proteins, metabolomics and transcriptional level both within single as well as multi-marker strategies. Moreover, their usefulness is focused on clinical decision-making in cardiovascular diseases.

Keywords: Cardiovascular disease; acute coronary syndrome; biomarker; heart failure; metabolome; micro-RNA; proteome.

PubMed Disclaimer

LinkOut - more resources